GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has entered into an agreement with fellow UK biotechnology firm Ochre Bio, announcing this week that it will pay up to USD 37.5 million for access to Ochre Bio’s human liver data. This strategic collaboration aims to bolster the development of hepatology therapies. The comprehensive data package encompasses both historical and future datasets, which have been derived using Ochre Bio’s advanced platforms in computational biology, single-cell sequencing, human organs, and large-scale gene perturbation.
Under this partnership, the companies will utilize the extensive databases to construct AI models, which are expected to enhance experimental design and deepen the understanding of liver function and disease mechanisms.- Flcube.com
